Selected investment case studies
Eight assignments showing how scientific, legal, operating, and structural evidence was converted into decisions—and revised when the facts changed.
Navigate the cases
Leading a $20 million structured financing around the world’s first Phase III preventive HIV-vaccine program—and managing the security as the clinical and corporate thesis changed.
VaxGen was funding two pivotal AIDSVAX programs before efficacy was known. The question was whether manufacturing and commercialization preparation could be financed while protecting against binary clinical risk, dilution, liquidity, and additional capital needs.
The work connected trial design, biological rationale, safety, regulatory pathway, manufacturing readiness, licensed technology, cash runway, and milestone timing. Scientific credibility had to be translated into an investable financing calendar.
The investment firm led a $20 million Series A financing and supplied $15 million through 6% cumulative redeemable convertible preferred stock and warrants, with liquidation priority, redemption rights, anti-dilution protection, registration rights, and specified consent protections.
The lead investor converted its preferred into common stock before the first pivotal readout. Both AIDSVAX trials later missed their primary efficacy endpoints, and VaxGen shifted toward biodefense. The case required security-level decisions as the original thesis changed fundamentally.
Direct origination and security design around a genuinely binary catalyst—plus the discipline to separate structural protection from the continuing need to reassess science, financing, liquidity, and strategy. The final position-level return is not stated because the surviving public record does not establish the complete exit.
Based on VaxGen SEC filings, contemporaneous reporting, government review, and transaction records. Certain portfolio-management details remain private.
Building, financing, and repeatedly re-underwriting a portfolio of mass-tort claims as legal, scientific, operational, and timing assumptions evolved.
The investable asset was a portfolio of contingent claims—not a conventional company or loan. The question was whether claims could be sourced, validated, acquired, financed, and monitored at a cost that left sufficient value after eligibility failures, fees, expenses, attrition, and delay.
Claimant eligibility, presence and duration at Camp Lejeune, medical evidence, disease category, water and exposure information, filing status, representation, duplicate records, and documentation quality had to be normalized across sourced inventories.
Claimant-level assumptions rolled into portfolio scenarios covering eligible-case conversion, recovery, fee sharing, acquisition cost, expenses, financing cost, duration, and concentration. Capital formation and funding timelines had to match acquisition and litigation needs.
The model evolved with docket developments, exposure analysis, disease differentiation, secondary-market indications, claimant quality, and operational experience. Inventories were monitored through intake, validation, documentation, filing, and resolution stages.
How to turn a large, messy claimant population into an underwritten portfolio: define the asset, test the data chain, price attrition and time, evaluate vendors and counsel, structure funding, and revise valuation as facts change. The portfolio remains described as ongoing; no unverified return or recovery figure is published.
Counterparties, claimant information, current portfolio marks, and proprietary assumptions are omitted or generalized.
Underwriting evolving science, exposure, claimant selection, and litigation risk across multiple sourced inventories.
Each claimant depended on a chain connecting disease, medical history, address or occupational history, exposure pathway, latency, competing causes, legal status, and supporting documents. The core question was which cohorts justified acquisition cost and development expense.
Address histories were connected to water systems and other exposure pathways; disease categories, latency, medical records, and alternative causes were reviewed. Historical geography mattered because residence in an affected region did not establish identical exposure for every claimant.
Valuation combined claimant screening with cohort assumptions for exposure strength, documentation, attrition, recovery, participation economics, costs, duration, financing expense, and concentration. Science and Rule 702/Daubert risk were modeled together with legal outcomes.
New scientific, evidentiary, and docket developments changed which diseases and exposure pathways were attractive. Vendor conversion, duplicates, documentation status, counsel, geography, and theory concentration were monitored across the portfolio.
The integration of science, legal standards, historical exposure data, vendor operations, claimant evidence, and financial modeling—followed by the harder step of changing selection criteria and portfolio value when the evidence evolves.
The law-firm and sourcing counterparties remain unnamed pending a separate disclosure decision.
Financing a predictive-biosimulation company with senior-secured convertible debt while underwriting its disease models as operating assets, intellectual property, and collateral.
The investment firm committed $5 million to 10% senior-secured convertible debentures in December 2007 and June 2008. With an illiquid public stock, principal protection had to come from seniority, collateral, covenants, and recoverable model value—not an assumed equity exit.
Entelos’s computer-based disease models combined scientific literature, clinical data, biological pathways, and partner research. The work tested whether the models generated repeat revenue, reusable know-how, defensible intellectual property, and strategic value to pharmaceutical partners.
The 10% debentures matured in December 2011, accreted interest for the first year, and were secured by company assets. Financial tests and restrictions on debt, equity financing, liens, cash flows, and asset sales preserved creditor control and restructuring leverage.
When 2008 performance weakened, the thesis shifted from growth and conversion upside toward cash preservation, partner demand, asset coverage, and covenant enforcement. The company went private and restructured while strategic interest and third-party bids informed collateral analysis.
Hybrid underwriting across healthcare science, software economics, intellectual property, and private credit. The contemporaneous record establishes the restructuring posture but not the investment firm’s final repayment or realized return, so no unsupported outcome is claimed.
Based on a contemporaneous investment summary and corroborating public information concerning Entelos’s platform, partners, and financing.
Leading a structured-equity financing for an automated cellular-imaging company, reducing exposure through active trading, and preserving value through a sponsor-supported restructuring.
ChromaVision’s automated microscope and imaging software supported pathologist analysis across a growing test menu. The investor had to finance adoption while managing the possibility that customer utilization, receivables, operating controls, and cash needs would lag headline growth.
The analysis connected installed systems to utilization, fee-per-use revenue, disposables, working capital, regulatory progress, and operating leverage. Trading volume and stock borrow were underwritten before closing because hedging was part of the risk plan.
The investor led a $12.5 million July 2001 financing of Series D 5% cumulative convertible preferred stock and warrants, with a $5 million lead position. Seniority, a three-year redemption, reset and anti-dilution provisions, warrants, and registration rights complemented active trading.
Exposure was reduced immediately. When adoption disappointed, the stock fell and liquidity tightened. With the stock below the reset floor and new financing likely to trigger anti-dilution rights, the investment moved into a negotiation with Safeguard Scientifics, the company’s largest shareholder.
Safeguard acquired most of the preferred, invested new common equity, and guaranteed additional debt. Harry’s contemporaneous record states that the investment firm received face value for the preferred, retained reset warrants, and earned approximately $1 million—nearly 20%—despite the common-equity collapse. It is a full-cycle example of structure, trading discipline, and negotiated exit working together.
Transaction terms and Safeguard’s restructuring are corroborated by ChromaVision SEC filings. The return is drawn from Harry’s contemporaneous investment record.
Months of operating, market, valuation, and capital-structure work on a fast-growing brand-acquisition platform—ending without an investment when the available security did not adequately protect the downside.
The company acquired and developed healthcare-oriented e-commerce brands, combining medical and regulatory knowledge with Amazon, direct-to-consumer, advertising, sourcing, and product-development capabilities. The central question was whether its acquisition and optimization engine justified the valuation and whether an investable security could be structured around the existing leverage.
The work separated an appealing healthcare narrative from the actual economic drivers: customer acquisition, marketplace ranking, advertising efficiency, conversion, repeat purchasing, procurement, inventory, brand extensions, and geographic expansion. Months of diligence examined acquisition sourcing, customer stickiness, contribution margins, operating leverage, integration capacity, and the repeatability of the brand-improvement playbook.
Management projected rapid growth through existing brands and repeated acquisitions. The analysis tested how organic growth, purchased revenue, advertising spend, working capital, earn-outs, debt drawdowns, interest expense, liquidity covenants, and future equity requirements interacted. Strong operating momentum could be real without making the full acquisition forecast—or the proposed security—safe.
The available preferred equity had liquidation priority over common stock but remained structurally behind a secured lender with claims on the operating assets. Alternative protections were explored, yet the financing requirements and existing collateral package meant a new investment would remain materially exposed in a downside case. The transaction was not completed.
Not every valuable assignment ends with capital deployment. This case shows the ability to dig deeply into a fast-growing operating platform, identify the real value drivers beneath the sector story, challenge acquisition-led projections, trace creditor priority, and allow capital structure to override enthusiasm for the business. The result was disciplined non-investment when the security could not be made commensurate with the risk.
The company, investment platform, counterparties, valuation, and confidential financing terms are intentionally omitted. No investment was completed.
Supporting a third-party private-equity firm with product-level commercial diligence, scenario valuation, pipeline analysis, and repeated multi-hour investment presentations.
The target combined two principal marketed products, a declining third product, and a development-stage pulmonary arterial hypertension program. The acquisition thesis depended on using cash flow from the commercial portfolio to support a potentially valuable clinical asset. The question was what the business was worth once generic entry, competitive intensity, geographic uncertainty, development cost, and time were treated realistically.
The work decomposed the company rather than applying one multiple to consolidated EBITDA. An established obesity product was assessed against generics, GLP-1 therapies, price-sensitive patients, and patients unable to remain on GLP-1s. A pancreatic-enzyme product was evaluated as a trusted but largely commoditized therapy competing through price, channel execution, positioning, and patient or prescriber loyalty.
The PAH program was analyzed separately as a risk-adjusted option: mechanism, regulatory pathway, orphan positioning, competing therapies, development cost, launch timing, pricing, market role, and cost of capital. The analysis made explicit that capital used to preserve the development option could not simultaneously support marketed products, acquisitions, or distributions.
Management, base, bear, and bull cases varied product growth, generic and international performance, EBITDA margins, operating expense, launch timing, and residual cash-flow assumptions. Marketed-product values ranged from approximately $167 million to $312 million. Separate pipeline cases ranged from roughly $41 million under a delayed path to approximately $98 million under a more favorable path.
The analysis was prepared for a third-party private-equity firm and presented multiple times in sessions lasting several hours. The work required explaining and defending product assumptions, valuation sensitivities, scientific risk, commercial competition, capital allocation, and the transaction implications of changing facts—not simply delivering a static model.
The view became more cautious as generic pressure, overseas challenges, geopolitics, tariffs, revised expectations, and margin vulnerability reduced visibility. The conclusion was that uncertainty should affect both purchase consideration and structure, with contingent value, milestones, or other risk-sharing mechanisms used to bridge disagreement.
This case demonstrates third-party investment judgment: mastering a complex pharmaceutical target, valuing marketed and clinical assets differently, building transparent scenarios, responding to new information, and defending conclusions before a sophisticated private-equity audience. It connects science, commercial analysis, financial modeling, transaction structure, and executive communication in one decision process.
The private-equity client, target company, advisers, proposed transaction structure, and ultimate acquisition outcome are intentionally omitted.
A multi-month HER4 Consulting engagement helping an early-stage technology company explain its story, build market awareness, and support its positioning with a formal valuation of its intellectual-property platform.
Exmovere Holdings directly retained and paid HER4 Consulting for investor-relations support over several months. The mandate was to help the company communicate an unusually broad and technically complex story spanning healthcare, security, mobility, biosensors, and emotion-related data in language that outside audiences could understand.
The work required finding the coherent investment narrative beneath a collection of developmental products and technologies: what the common platform was, why the products belonged together, which markets mattered, how the pieces reinforced one another, and where future commercial value might emerge. The objective was to help Exmovere tell that story more clearly and gain awareness without reducing it to unsupported promotion.
The 35-page report assessed six principal product and business platforms, their intellectual-property foundations, licensing relationships, addressable markets, commercialization paths, and strategic interdependence. Management projections informed the work but were not accepted wholesale.
Because the products were early and could be commercialized internally, partnered, or licensed, the report used a discounted royalty and composite-revenue framework. Product-level market growth, penetration, royalty economics, overhead, taxes, residual growth, and 30%–35% discount rates were made explicit across multiple scenarios.
The analysis argued that the portfolio could not be understood simply as a collection of isolated inventions. Shared biosensor technology, data generation, clinical use, operating platforms, and cross-market validation created an interconnected intangible-asset base whose value depended on both individual products and their combined strategic use.
The completed engagement gave prospective investors a structured analytical basis for understanding and evaluating an unusual early-stage technology company. The report also documented its due diligence, assumptions, reliance on company information, restrictions, relationship to the client, and the uncertainty inherent in valuing developmental technology.
A more disciplined, evidence-based presentation of the company helped generate investor interest. Over time, however, management’s expectations moved beyond what the available operating and market evidence could reasonably support. The engagement ended rather than allowing investor-relations work to become detached from analytical judgment.
A multi-month operating advisory engagement under the HER4 name: learning a technically complex company, shaping an intelligible investment narrative, helping it build awareness and investor interest, and grounding that narrative in a documented valuation opinion that could be explained, challenged, and defended. It also required managing an ambitious client and preserving analytical independence when expectations became unrealistic. This was paid third-party investor-relations and valuation work—not an investment by HER4 or an affiliated fund.
The engagement history and subsequent investor interest are based on Harry Russell’s direct account. The analytical record includes the final 35-page Exmovere Intangible Asset Assessment prepared by HER4 Consulting and dated June 30, 2010. The valuation was an advisory opinion based on information and assumptions available at that time, not a subsequent transaction price.
Selected published research
Before returning to buy-side investing, Harry published biotechnology and healthcare equity research. The examples below are presented as evidence of the work—not as a comprehensive investment-performance record. Most recommendations made in buy-side roles were proprietary and were never publicly published.
The initiation identified the importance of ponatinib, favorable emerging clinical evidence, multiple near-term catalysts, and the company’s capacity to finance development.
The shares exceeded the report’s stated target within nine months.
The trading call identified material regulatory and valuation risk ahead of the FDA’s Bydureon decision and established a downside target before the event.
The shares declined through the report’s downside target following the subsequent regulatory setback.
Additional surviving reports include published work on Celgene, Amgen, Gilead, and NexMed/Apricus, along with earlier independent biotechnology research. These materials demonstrate breadth of company, product, clinical, valuation, and catalyst analysis; they are not presented here as a selectively reconstructed track record.
Historical prices are shown solely to provide context for the two contemporaneous recommendations. They do not represent a complete record, audited performance, or an indication of future results.
Certain names, counterparties, transaction terms, proprietary assumptions, and investment conclusions have been omitted or generalized for confidentiality. These case studies describe historical analytical experience and are not offers, recommendations, or indications of future results.
Independent perspective. Institutional discipline. Clear recommendations.